Section
The STEEER-AF cluster-randomized trial reveals that structured professional education significantly boosts adherence to complex rhythm control guidelines in atrial fibrillation, though it shows no significant impact on stroke prevention whe
The 128-week follow-up of the VALOR-HCM trial demonstrates that mavacamten provides sustained relief from LVOT obstruction, promotes favorable cardiac remodeling, and significantly reduces the need for invasive septal reduction therapy in p
The PARTHENOPE randomized trial demonstrates that personalizing DAPT duration (3 to 24 months) based on individual risk scores significantly reduces net adverse clinical events compared to standard 12-month therapy, primarily by lowering is
A prespecified analysis of the FINEARTS-HF trial confirms that finerenone reduces cardiovascular death and heart failure events in patients with HFmrEF and HFpEF across all symptomatic stages, offering the greatest absolute benefit to those
The ESPRIT trial reveals that targeting systolic blood pressure below 120 mmHg significantly reduces cardiovascular events across diverse populations, including frail patients and those with diabetes, while uniquely improving retinal microv
A multicenter RCT found that ethosuximide, a T-type calcium channel blocker, did not improve abdominal pain in IBS patients compared to placebo and was associated with significant tolerability issues, highlighting the need for more selectiv
A multicenter stepped-wedge trial reveals that while prospective audit and feedback by stewardship teams improves the quality of discharge antibiotic prescribing, it fails to reduce the overall volume or duration of therapy, highlighting th
This randomized clinical trial investigates whether returning opportunistic genomic results for familial hypercholesterolemia to veterans impacts LDL-C levels. While the primary endpoint missed statistical significance, the findings suggest
The Phase 2a ENV-IPF-101 trial demonstrates that taladegib, a Hedgehog pathway inhibitor, not only stabilizes but may improve forced vital capacity and reduce fibrotic burden in patients with idiopathic pulmonary fibrosis over 12 weeks.
A rigorous clinical trial reveals that five weeks of resveratrol supplementation does not improve blood sugar, GLP-1 levels, or gastric emptying in patients with type 2 diabetes.
A randomized trial demonstrates that Dibifree, a novel dietary phytomix, improves HbA1c and adiposity in T2D patients by enhancing GLP-1 activity and modulating immune responses.
A large-scale analysis of UK dietary data reveals that higher alignment with the EAT-Lancet planetary health diet significantly improves the intake of essential micronutrients like iron, zinc, and calcium, refuting concerns that sustainable
A randomized clinical trial reveals that while Limosilactobacillus reuteri probiotics do not enhance local periodontal healing compared to standard therapy, they significantly improve systemic glycemic control (HbA1c) in patients with diabe
A major long-term trial reveals that a moderate-protein, moderate-glycaemic index diet is more effective for sustaining prediabetes remission than high-protein alternatives, regardless of total weight loss.
A 12-week randomized controlled trial demonstrates that prioritizing slowly digestible starch (SDS) through dietary and culinary counseling significantly reduces glycemic variability and helps patients with type 2 diabetes achieve target Hb
A landmark study reveals that automated insulin delivery systems significantly improve blood sugar control for adults with type 2 diabetes, regardless of their C-peptide levels, challenging current insurance restrictions that limit access t
A comprehensive analysis of the 46 novel drugs approved by the FDA in 2025, highlighting breakthroughs in oncology, chronic pain, and respiratory medicine, alongside significant regulatory changes and a preview of the 2026 pipeline.
A large-scale cohort study demonstrates that the efficacy of dual antiplatelet therapy for minor stroke and TIA is highly time-dependent, with maximal benefits seen within 24 hours and a loss of therapeutic effect after approximately 42 hou
The BE IMMUNE randomized trial demonstrates that combining patient text reminders, clinician EHR pended orders, and peer comparisons increases flu vaccination by 5.1 percentage points among adults aged 50 and older, highlighting the efficac
The ADJUST-DVT study confirms that an age-adjusted D-dimer cutoff (age × 10 µg/L) safely increases the number of patients in whom deep vein thrombosis can be ruled out without imaging, particularly benefiting patients over 75 years of age.
